Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 clinical trials
Also written PIT565.
Its developmentBy Novartis, step by step3 company-led studies, furthest phase 1: when each phase was reached, its deals, target and what is ahead.- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PIT565
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565.
- Jan 2027Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesPhase 1 · Novartis Pharmaceuticals
- Nov 2027An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).Phase 1 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of PIT565 in Relapsed and/or Refractory B-cell MalignanciesActive, not recruitingPhase 1Novartis PharmaceuticalsNCT05397496Written as PIT565
- An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).Active, not recruitingPhase 1Novartis PharmaceuticalsNCT06335979Written as PIT565
- An Ascending Dose Study of PIT565 in Participants With Rheumatoid ArthritisActive, not recruitingPhase 1Novartis PharmaceuticalsNCT07029555Written as PIT565